Is there any role for additional chemotherapy for a pre-menopausal woman with locally advanced ER+, Her2- IDC, with residual disease after neoadjuvant AC?  

Locally advanced higher risk disease should get both AC and a taxane in either the neoadjuvant or adjuvant setting. So for ER+ disease I would give the taxane adjuvantly then move on to radiation and endocrine therapy in this case. 

That there would be residual disease after Neoadjuvant chemotherapy is not a  surprise due to the biology and the main strategy for long time cure and control is the endocrine therapy that follows.